82 FR 17011 - Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 82, Issue 66 (April 7, 2017)
Centers for Disease Control and Prevention
Federal Register Volume 82, Issue 66 (April 7, 2017)
| Page Range | 17011-17011 | |
| FR Document | 2017-06984 |
[Federal Register Volume 82, Number 66 (Friday, April 7, 2017)] [Notices] [Page 17011] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-06984] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement, RFA-CE- 17-003, Research Grant for Preventing Violence and Violence Related Injury (R01). Times and Dates: 08:00 a.m.-5:00 p.m., EDT, May 11, 2017 (Closed) 8:00 a.m.-5:00 p.m., EDT, May 12, 2017 (Closed). Place: The Georgian Terrace, 659 Peachtree Street NE., Atlanta, Georgia 30308. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ``Research Grant for Preventing Violence and Violence Related Injury (R01)'', RFA-CE-17-003. Contact Person for More Information: Kimberly Leeks, Ph.D., M.P.H., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F78, Atlanta, Georgia 30341-3717, Telephone: (770) 488-5964. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017-06984 Filed 4-6-17; 8:45 am] BILLING CODE 4163-18-P
![Federal Register / Vol. 82, No. 66 / Friday, April 7, 2017 / Notices 17011
Time and Date: 10:00 a.m.–6:00 p.m., a.m.–5:00 p.m., EDT, May 12, 2017 is establishing a docket for public
EDT, May 9, 2017 (Closed). (Closed). comment on this document.
Place: Teleconference. Place: The Georgian Terrace, 659 DATES: The meeting will be held on
Status: The meeting will be closed to Peachtree Street NE., Atlanta, Georgia April 13, 2017, from 8:30 a.m. to 5 p.m.
the public in accordance with 30308. The docket number is FDA–2017–N–
provisions set forth in Section 552b(c) Status: The meeting will be closed to 1813. The docket will close on April 12,
(4) and (6), Title 5 U.S.C., and the the public in accordance with 2017. Comments received on or before
Determination of the Director, provisions set forth in Section 552b(c) April 10, 2017, will be provided to the
Management Analysis and Services (4) and (6), Title 5 U.S.C., and the committee. Comments received after
Office, CDC, pursuant to Public Law 92– Determination of the Director, that date will be taken into
463. Management Analysis and Services consideration by the Agency.
Matters for Discussion: The meeting Office, CDC, pursuant to Public Law 92– ADDRESSES: Tommy Douglas Conference
will include the initial review, 463. Center, the Ballroom, 10000 New
discussion, and evaluation of Matters for Discussion: The meeting Hampshire Ave., Silver Spring, MD
applications received in response to will include the initial review, 20903. The conference center’s
‘‘Formative Study of Patient Navigators discussion, and evaluation of telephone number is 240–645–4000.
with the National Breast and Cervical applications received in response to Answers to commonly asked questions
Cancer Early Detection Program ‘‘Research Grant for Preventing Violence including information regarding special
(NBCCEDP) and the Colorectal Cancer and Violence Related Injury (R01)’’, accommodations due to a disability,
Control Program (CRCCP)’’, SIP 17–003 RFA–CE–17–003. visitor parking, and transportation may
and ‘‘Assessing the Lifetime Economic Contact Person for More Information: be accessed at: http://www.fda.gov/
Burden in Younger, Midlife, and Older Kimberly Leeks, Ph.D., M.P.H., AdvisoryCommittees/
Women with Metastatic Breast Cancer’’, Scientific Review Officer, CDC, 4770 AboutAdvisoryCommittees/
SIP 17–004. Buford Highway NE., Mailstop F78, ucm408555.htm.
Contact Person for More Information: Atlanta, Georgia 30341–3717, You may submit comments as
Jaya Raman Ph.D., Scientific Review Telephone: (770) 488–5964. follows:
Officer, CDC, 4770 Buford Highway, The Director, Management Analysis
Mailstop F80, Atlanta, Georgia 30341, Electronic Submissions
and Services Office, has been delegated
Telephone: (770) 488–6511, kva5@ the authority to sign Federal Register Submit electronic comments in the
cdc.gov. notices pertaining to announcements of following way:
The Director, Management Analysis meetings and other committee • Federal eRulemaking Portal:
and Services Office, has been delegated management activities, for both the https://www.regulations.gov. Follow the
the authority to sign Federal Register Centers for Disease Control and instructions for submitting comments.
notices pertaining to announcements of Prevention and the Agency for Toxic Comments submitted electronically,
meetings and other committee Substances and Disease Registry. including attachments, to https://
management activities, for both the www.regulations.gov will be posted to
Centers for Disease Control and Elaine L. Baker, the docket unchanged. Because your
Prevention and the Agency for Toxic Director, Management Analysis and Services comment will be made public, you are
Substances and Disease Registry. Office, Centers for Disease Control and solely responsible for ensuring that your
Prevention. comment does not include any
Elaine L. Baker, [FR Doc. 2017–06984 Filed 4–6–17; 8:45 am] confidential information that you or a
Director, Management Analysis and Services BILLING CODE 4163–18–P third party may not wish to be posted,
Office, Centers for Disease Control and
such as medical information, your or
Prevention.
anyone else’s Social Security number, or
[FR Doc. 2017–06979 Filed 4–6–17; 8:45 am] DEPARTMENT OF HEALTH AND confidential business information, such
BILLING CODE 4163–18–P HUMAN SERVICES as a manufacturing process. Please note
that if you include your name, contact
Food and Drug Administration information, or other information that
DEPARTMENT OF HEALTH AND
[Docket No. FDA–2017–N–1813] identifies you in the body of your
HUMAN SERVICES
comments, that information will be
Centers for Disease Control and Antimicrobial Drugs Advisory posted on https://www.regulations.gov.
Prevention Committee; Notice of Meeting; • If you want to submit a comment
Establishment of a Public Docket; with confidential information that you
Disease, Disability, and Injury Request for Comments do not wish to be made available to the
Prevention and Control Special public, submit the comment as a
Emphasis Panel (SEP): Initial Review AGENCY: Food and Drug Administration, written/paper submission and in the
HHS. manner detailed (see ‘‘Written/Paper
In accordance with Section 10(a)(2) of ACTION: Notice; establishment of public Submissions’’ and ‘‘Instructions’’).
the Federal Advisory Committee Act docket; request for comments.
(Pub. L. 92–463), the Centers for Disease Written/Paper Submissions
Control and Prevention (CDC) SUMMARY: The Food and Drug Submit written/paper submissions as
announces a meeting for the initial Administration (FDA) announces a follows:
nlaroche on DSK30NT082PROD with NOTICES
review of applications in response to forthcoming public advisory committee • Mail/Hand delivery/Courier (for
Funding Opportunity Announcement, meeting of the Antimicrobial Drugs written/paper submissions): Division of
RFA–CE–17–003, Research Grant for Advisory Committee. The general Dockets Management (HFA–305), Food
Preventing Violence and Violence function of the committee is to provide and Drug Administration, 5630 Fishers
Related Injury (R01). advice and recommendations to the Lane, Rm. 1061, Rockville, MD 20852.
Times and Dates: 08:00 a.m.–5:00 Agency on FDA’s regulatory issues. The • For written/paper comments
p.m., EDT, May 11, 2017 (Closed) 8:00 meeting will be open to the public. FDA submitted to the Division of Dockets
VerDate Sep<11>2014 17:15 Apr 06, 2017 Jkt 241001 PO 00000 Frm 00023 Fmt 4703 Sfmt 4703 E:\FR\FM\07APN1.SGM 07APN1](https://thefederalregister.org/doc/82_FR_17077/page/1.svg)
Document Created: 2017-04-06 23:49:24
Document Modified: 2017-04-06 23:49:24
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | 08:00 a.m.-5:00 p.m., EDT, May 11, 2017 (Closed) 8:00 a.m.-5:00 p.m., EDT, May 12, 2017 (Closed). | |
| FR Citation | 82 FR 17011 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR